|
1. Biologie
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
Stanford tobacco researcher weighs in on JUUL [Stanford Medicine]
|
|
|
|
|
|
JUUL
sells their products in the U.K., Canada, Israel, and will soon be in
Asia. In the U.K., 85 percent of teens are on Instagram. JUUL’s decision
to halt its social media only in the U.S. suggests that their action is
more a defensive tactic in response to threatened regulation than a
genuine commitment to stemming underage use.
|
|
|
|
|
|
|
|
|
|
|
3.4 Chimioprévention
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
NCI-MATCH Update: More Labs, New Arms, and Initial Findings [NCI]
|
|
|
|
|
|
NCI-MATCH
is very much a dynamic, ongoing trial, and it is poised to generate
additional results for months and years to come. Several treatment arms
for rare molecular alterations continue to enroll patients. Five arms
have recently been added, and another four arms will be added in the
next six months.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
NICE recommends cutting-edge therapy for young people with blood cancer [NICE]
|
|
|
|
|
|
Young
people with relapsed or refractory B-cell acute lymphoblastic leukaemia
(ALL) will now have access to tisagenlecleucel, also known as Kymriah
made by Novartis, through the Cancer Drugs Fund (CDF). Around 25 to
30 people will be eligible for tisagenlecleucel each year in England and
a specialised NHS service is being developed to manage access to the
new therapy.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.9.4 ENA
|
|
|
Patients with rare, incurable digestive tract cancers respond to new drug combination [ECCO]
|
|
|
|
|
|
Dr
Zev Wainberg reported on results from a phase II international clinical
trial of dabrafenib plus trametinib in 36 patients with biliary tract
cancer (BTC) and adenocarcinoma of the small intestine (ASI). These
patients had one of the most common mutations in the BRAF gene –BRAF
V600E – which is implicated in a number of cancers and in about 15% of
BTC and ASI cancers.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
China’s crackdown on genetics breaches could deter data sharing [Nature]
|
|
|
|
|
|
China’s
enormous population is a genetics goldmine. But the government, wary
that this data could be exploited for profit, has been cracking down on
researchers and companies that violate rules on sharing its citizens’
genetic material and information. Some scientists fear that this closer
attention is creating hurdles for international collaborations.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|